A. Gill

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

S. Gregory, H. Scher, Jun Luo, 2021, Clinical Cancer Research.

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

M. Gonen, H. Scher, J. Luo, 2021, European Journal of Cancer.

Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer

David S. K. Lu, H. Scher, R. Krupa, 2020, Journal of circulating biomarkers.

Morphology-Predicted Large-Scale Transition Number in Circulating Tumor Cells Identifies a Chromosomal Instability Biomarker Associated with Poor Outcome in Castration-Resistant Prostate Cancer

M. Gonen, H. Scher, Yipeng Wang, 2020, Cancer Research.

CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

J. Bono, B. Tombal, C. Sternberg, 2021 .

A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models

Nicholas E. Propson, K. Scearce-Levie, Steve Lianoglou, 2023, Nature Neuroscience.

CD98hc is a target for brain delivery of biotherapeutics

Katrina W. Lexa, K. Gadkar, R. Watts, 2023, Nature communications.